Close this search box.
Close this search box.

BioSante CEO Stephen Simes: Leveraging Libido

How does BioSante, a small pharmaceutical company that took in $2.5 million in revenue in 2010, expect to compete in the multi-billion dollar pharma industry? By being patient, outlasting the pharma giants, and introducing a new drug to fill a gap in the market.
BioSante CEO Stephen Simes

BioSante CEO Stephen Simes

More than a decade after the introduction of Viagra, which spawned an everbroadening market for treating male sexual dysfunction, there’s still no equivalent product for women. That’s something BioSante CEO Stephen Simes aims to change with LibiGel, a transdermal testosterone gel treatment for female sexual dysfunction or the best testosterone booster. “There is a real unmet medical need here,” he says, noting that the sexual dysfunction market is at least as large—if not larger—for women as it is for men.

In fact, 43 percent of women surveyed in a University of Chicago study reported experiencing sexual dysfunction, as compared with 31 percent of men. What’s more, each year an estimated four million off-label prescriptions (or pharmaceutical drugs prescribed for conditions other than those for which they were approved by the FDA) are written by gynecologists for hypoactive sexual desire disorder—the main component of female sexual dysfunction, says Simes. Those figures suggest a healthy potential demand for BioSante’s entry, LibiGel, which has been shown to increase women’s sexual desire and activity and decrease sexual distress. “At four million prescriptions, we’re looking at a $1 billion to $1.5 billion annual market—a potential blockbuster.”

How did little BioSante—which reported revenues of just under $2.5 million for 2010 and has sunk an estimated $100 million into the development of LibiGel—swing a first-to-market position in the behemoth-dominated pharma industry? Put succinctly, it simply outlasted its competitors. Simes says that Procter & Gamble had a similar product in development, but dropped out of the FDA approval process. And another potential contender, German company Boehringer Ingelheim, reportedly faltered due to poor results in Phase III clinical trials.

Meanwhile Lincolnshire, Ill.-based BioSante—which currently markets a treatment for hot flashes known as Elestrin—achieved strong results in Phase II clinical trials and is now in the midst of two Phase III safety and efficacy clinical trials. “The first women enrolled recently reached the third year on therapy,” reports Simes, who says results have been promising. “Our agreement with the FDA is that we can submit the new drug application and get approval based on an average of 12 months of exposure, which we now have. So we hope to submit by the end of this year for approval in 2012.”

But even assuming FDA approval—a big assumption, as the FDA is infamous for last minute upsets—BioSante faces additional hurdles in realizing LibiGel’s potential. The biggest will be finding a partner with the marketing and distribution wherewithal to bring the product to market, or selling the company outright.

Simes is sanguine about both options. “For a partnership, we would need to get something in place in the next 12 to 18 months because by then we could very well have FDA approval,” he says.

“But both avenues are attractive to us. My job as CEO is to not only run the company and make progress, but to maximize stockholder value in whatever form that comes.”


  • Get the CEO Briefing

    Sign up today to get weekly access to the latest issues affecting CEOs in every industry
  • upcoming events


    Strategic Planning Workshop

    1:00 - 5:00 pm

    Over 70% of Executives Surveyed Agree: Many Strategic Planning Efforts Lack Systematic Approach Tips for Enhancing Your Strategic Planning Process

    Executives expressed frustration with their current strategic planning process. Issues include:

    1. Lack of systematic approach (70%)
    2. Laundry lists without prioritization (68%)
    3. Decisions based on personalities rather than facts and information (65%)


    Steve Rutan and Denise Harrison have put together an afternoon workshop that will provide the tools you need to address these concerns.  They have worked with hundreds of executives to develop a systematic approach that will enable your team to make better decisions during strategic planning.  Steve and Denise will walk you through exercises for prioritizing your lists and steps that will reset and reinvigorate your process.  This will be a hands-on workshop that will enable you to think about your business as you use the tools that are being presented.  If you are ready for a Strategic Planning tune-up, select this workshop in your registration form.  The additional fee of $695 will be added to your total.

    To sign up, select this option in your registration form. Additional fee of $695 will be added to your total.

    New York, NY: ​​​Chief Executive's Corporate Citizenship Awards 2017

    Women in Leadership Seminar and Peer Discussion

    2:00 - 5:00 pm

    Female leaders face the same issues all leaders do, but they often face additional challenges too. In this peer session, we will facilitate a discussion of best practices and how to overcome common barriers to help women leaders be more effective within and outside their organizations. 

    Limited space available.

    To sign up, select this option in your registration form. Additional fee of $495 will be added to your total.

    Golf Outing

    10:30 - 5:00 pm
    General’s Retreat at Hermitage Golf Course
    Sponsored by UBS

    General’s Retreat, built in 1986 with architect Gary Roger Baird, has been voted the “Best Golf Course in Nashville” and is a “must play” when visiting the Nashville, Tennessee area. With the beautiful setting along the Cumberland River, golfers of all capabilities will thoroughly enjoy the golf, scenery and hospitality.

    The golf outing fee includes transportation to and from the hotel, greens/cart fees, use of practice facilities, and boxed lunch. The bus will leave the hotel at 10:30 am for a noon shotgun start and return to the hotel after the cocktail reception following the completion of the round.

    To sign up, select this option in your registration form. Additional fee of $295 will be added to your total.